Department of Cardiology, Cardiac Catheterization Laboratory 2014, The Heart Centre, Rigshospitalet, University of Copenhagen, 2100 Copenhagen Ø, Denmark.
Inflamm Res. 2010 Jun;59(6):463-9. doi: 10.1007/s00011-009-0146-z. Epub 2009 Dec 10.
To study plasma YKL-40 in patients with atrial fibrillation (AF) treated with radiofrequency (RF) catheter ablation and to assess the predictive role of plasma YKL-40 and its changes after restoration of sinus rhythm (SR).
Forty-six patients (mean age 55 years, range 31-81) with paroxysmal/persistent AF were treated with RF catheter ablation; Holter monitoring for 14 days was performed before ablation and after 3 months. Recurrent symptomatic AF or atrial tachycardia >10 min was considered failure, and the patients were offered a second ablation session. YKL-40 was determined in plasma samples taken prior to ablation and at follow-up visits up to 12 months after ablation.
After a maximum of two ablations, 19 patients (41%) had SR without recurrence of AF after 12 months. The patients with no recurrence of AF had significantly lower baseline plasma levels of YKL-40 prior to ablation compared to patients with recurrence of AF (31 vs. 62 microg/l, P = 0.029). Plasma YKL-40 was not an independent predictor of recurrence of AF after ablation. No significant changes in plasma YKL-40 levels were seen from baseline to follow-up at 12 months.
In patients with paroxysmal or persistent AF treated with catheter ablation, high plasma YKL-40 before ablation is associated with recurrence of AF.
研究射频（RF）导管消融治疗的心房颤动（AF）患者的血浆 YKL-40，并评估血浆 YKL-40 及其恢复窦性心律（SR）后的变化的预测作用。
46 例阵发性/持续性 AF 患者（平均年龄 55 岁，范围 31-81 岁）接受 RF 导管消融治疗；消融前和 3 个月后进行 14 天动态心电图监测。有症状的 AF 复发或 >10 分钟的房性心动过速被认为是失败，患者接受了第二次消融治疗。在消融前和消融后 12 个月的随访中，测定血浆 YKL-40。
在最多两次消融后，19 例（41%）患者在 12 个月后无 AF 复发且维持 SR。无 AF 复发的患者在消融前的基础血浆 YKL-40 水平明显低于有 AF 复发的患者（31 与 62 microg/l，P = 0.029）。消融后，血浆 YKL-40 并不是 AF 复发的独立预测因子。从基线到 12 个月的随访，血浆 YKL-40 水平无显著变化。
在接受导管消融治疗的阵发性或持续性 AF 患者中，消融前高血浆 YKL-40 与 AF 复发相关。
